G42, a health-tech company, agreed to acquire a minority stake in vTv Therapeutics, a clinical stage biopharmaceutical company, for $25m. “We have a deep commitment to collaborating with international organizations to share our knowledge and expertise in the consumer and clinical health spectrum and we look forward to working together with vTv to further develop and commercialize this important treatment. As we move ahead, we will continue to join forces with the world’s best to innovate and invest in science and create the next wave of medicines to future-proof the health of nations,” Fahed Al Marzooqi, G42 Healthcare Chief Operating Officer.